

'Successful world class results' Lions Eye Institute news release

**25 May 2020:** The Lions Eye Institute (LEI), PYC Therapeutics' (PYC or the Company) joint venture partner in our 90% owned subsidiary Vision Pharma Pty Ltd (Vision), has made a news release regarding recent progress made by Vision that is available on both PYC and LEI's websites.

The link to the LEI news release on PYC's website is copied below.

<https://pyctx.com/wp-content/uploads/2020/05/successful-world-class-results.pdf>

The release is also available on the LEI website under the title:

*'Successful world class results announced for Retinitis Pigmentosa'*

The article can be summarised as follows:

*'The Lions Eye Institute alongside PYC Therapeutics have been progressing a highly promising drug for the treatment of the leading cause of childhood blindness, Retinitis Pigmentosa (RP) (see PYC ASX announcements of 1 and 8 April 2020).*

*RP is a debilitating condition that begins in childhood and leads to blindness in patients between the ages of 20 and 40. There are no treatment options currently for these patients aside from counselling. The progression to blindness significantly impacts the personal lives and livelihood of those patients affected and the people who support them.*

*The ground-breaking research for this new treatment took place within the Lions Eye Institute's Ocular Tissue Engineering Lab in Nedlands, Western Australia. The Lions Eye Institute's Dr Fred K. Chen and his team, worked with Prof. Sue Fletcher, Chief of Research and Development at PYC and of Murdoch University and her team to achieve these amazing results.'*

*This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.*

**ENDS** For further information, please contact:

Kaggen Ausma  
CBO  
info@pyctx.com

## About PYC Therapeutics

*PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

## Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

pyctx.com

**PYC Therapeutics**

ACN 098 391 961